15
Participants
Start Date
November 30, 2008
Primary Completion Date
December 31, 2011
Study Completion Date
December 31, 2011
CC-100004
After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis.
University of Cincinnati, Cincinnati
Collaborators (1)
Celgene Corporation
INDUSTRY
Medical University of South Carolina
OTHER
University of Cincinnati
OTHER